Heterozygous mutations in the straitjacket region of the latency-associated peptide domain of TGFB2 cause Camurati-Engelmann disease type II.
Journal
Journal of human genetics
ISSN: 1435-232X
Titre abrégé: J Hum Genet
Pays: England
ID NLM: 9808008
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
received:
12
04
2024
accepted:
03
07
2024
revised:
03
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
16
7
2024
Statut:
aheadofprint
Résumé
Camurati-Engelmann disease (CED) is an autosomal dominant bone dysplasia characterized by progressive hyperostosis of the skull base and diaphyses of the long bones. CED is further divided into two subtypes, CED1 and CED2, according to the presence or absence of TGFB1 mutations, respectively. In this study, we used exome sequencing to investigate the genetic cause of CED2 in three pedigrees and identified two de novo heterozygous mutations in TGFB2 among the three patients. Both mutations were located in the region of the gene encoding the straitjacket subdomain of the latency-associated peptide (LAP) of pro-TGF-β2. Structural simulations of the mutant LAPs suggested that the mutations could cause significant conformational changes and lead to a reduction in TGF-β2 inactivation. An activity assay confirmed a significant increase in TGF-β2/SMAD signaling. In vitro osteogenic differentiation experiment using iPS cells from one of the CED2 patients showed significantly enhanced ossification, suggesting that the pathogenic mechanism of CED2 is increased activation of TGF-β2 by loss-of-function of the LAP. These results, in combination with the difference in hyperostosis patterns between CED1 and CED2, suggest distinct functions between TGFB1 and TGFB2 in human skeletal development and homeostasis.
Identifiants
pubmed: 39014191
doi: 10.1038/s10038-024-01274-1
pii: 10.1038/s10038-024-01274-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to The Japan Society of Human Genetics.
Références
Mortier GR, Cohn DH, Cormier-Daire V, Hall C, Krakow D, Mundlos S, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet Part A. 2019;179:2393–419.
doi: 10.1002/ajmg.a.61366
pubmed: 31633310
Camurati M. Di un raro caso di osteite simmetrica erditaria degli arti inferiori. Chir Organ Mov. 1922;6:662–5.
Engelmann G. Ein Fall von Osteopathia Hyperosteotica (sclerotisans) multiplex infantilis. Fortschr Rontgenstr. 1929;39:1101–6.
Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, et al. Camurati–Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet. 2006;43:1–11.
doi: 10.1136/jmg.2005.033522
pubmed: 15894597
pmcid: 2564495
Ghadami M, Makita Y, Yoshida K, Nishimura G, Fukushima Y, Wakui K, et al. Genetic mapping of the Camurati–Engelmann disease locus to chromosome 19q13.1-q13.3. Am J Hum Genet. 2000;66:143–7.
doi: 10.1086/302728
pubmed: 10631145
Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, et al. Domain-specific mutations in TGFB1 result in Camurati–Engelmann disease. Nat Genet. 2000;26:19–20.
doi: 10.1038/79128
pubmed: 10973241
Hecht JT, Blanton SH, Broussard S, Scott A, Rhoades Hall C, Milunsky JM. Evidence for locus heterogeneity in the Camurati–Engelmann (DPD1) syndrome. Clin Genet. 2001;59:198–200.
doi: 10.1034/j.1399-0004.2001.590310.x
pubmed: 11260231
Nishimura G, Nishimura H, Tanaka Y, Makita Y, Ikegawa S, Ghadami M, et al. Camurati–Engelmann disease type II: progressive diaphyseal dysplasia with striations of the bones. Am J Med Genet. 2002;107:5–11.
doi: 10.1002/ajmg.10079
pubmed: 11807860
Wang Z, Horemuzova E, Iida A, Guo L, Liu Y, Matsumoto N, et al. Axial spondylometaphyseal dysplasia is also caused by NEK1 mutations. J Hum Genet. 2017;62:503–6.
doi: 10.1038/jhg.2016.157
pubmed: 28123176
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.
doi: 10.1101/gr.107524.110
pubmed: 20644199
pmcid: 2928508
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164–e164.
doi: 10.1093/nar/gkq603
pubmed: 20601685
pmcid: 2938201
Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015;12:7–8.
doi: 10.1038/nmeth.3213
pubmed: 25549265
pmcid: 4428668
Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, et al. Latent TGF-β structure and activation. Nature. 2011;474:343–9.
doi: 10.1038/nature10152
pubmed: 21677751
pmcid: 4717672
Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33:W382–W388.
doi: 10.1093/nar/gki387
pubmed: 15980494
pmcid: 1160148
Janssens K, ten Dijke P, Ralston SH, Bergmann C, Van Hul W. Transforming growth factor-β1 mutations in Camurati–Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J Biol Chem. 2003;278:7718–24.
doi: 10.1074/jbc.M208857200
pubmed: 12493741
Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8:409–12.
doi: 10.1038/nmeth.1591
pubmed: 21460823
Fukuta M, Nakai Y, Kirino K, Nakagawa M, Sekiguchi K, Nagata S, et al. Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media. PLoS ONE. 2014;9:e112291.
doi: 10.1371/journal.pone.0112291
pubmed: 25464501
pmcid: 4251837
Walton KL, Makanji Y, Chen J, Wilce MC, Chan KL, Robertson DM, et al. Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J Biol Chem. 2010;285:17029–37.
doi: 10.1074/jbc.M110.110288
pubmed: 20308061
pmcid: 2878044
Saito T, Kinoshita A, Yoshiura KI, Makita Y, Wakui K, Honke K, et al. Domain-specific mutations of a transforming growth factor (TGF)-β1 latency-associated peptide cause Camurati–Engelmann disease because of the formation of a constitutively active form of TGF-β1. J Biol Chem. 2001;276:11469–72.
doi: 10.1074/jbc.C000859200
pubmed: 11278244
Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-β: biological function and chemical structure. Science. 1986;233:532–4.
doi: 10.1126/science.3487831
pubmed: 3487831
Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet. 2001;29:117–29.
doi: 10.1038/ng1001-117
pubmed: 11586292